Update information
May 2024: Recommendation 1.2 was updated and replaced by NICE technology appraisal guidance on pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.
ISBN: 978-1-4731-6008-8
May 2024: Recommendation 1.2 was updated and replaced by NICE technology appraisal guidance on pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.
ISBN: 978-1-4731-6008-8